Product Name: Pitavastatin calcium
Synonyms: 147526-32-7 Pitavastatin Calcium;Pitavastatin Calcuim;Pitavastatin calcium, >=98.5%;Pitavastatin (calcium salt);monocalciumbis[(3R,5S,6E)-7-(2-Cyclopropyl-4-(4-Fluorophenyl)-3-Quinolyl)-3,5-Dihydroxy-6-heptenoate](+)a- Phenethylamine Sal;Pitavastatin Calciu;Calcium (3R,5S,E)-7-(2-cyclopropyl-4-(4-fluorophenyl)-quinolin-3-yl)-3,5-dihydroxyhept-6-enoat;PITAVASTATIN CALCIUM 3S-5R ISOMER IMP
CAS: 147526-32-7
MF: C50H46CaF2N2O8
MW: 880.98
EINECS: 807-641-2
Product Categories: Cardiovascular Series;Active Pharmaceutical Ingredients;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;chemical;API;Livalo
Mol File: 147526-32-7.mol

Pitavastatin calcium Chemical Properties
alpha  D20 +23.1° (c = 1.00 in acetonitrile/water)
CAS DataBase Reference 147526-32-7(CAS DataBase Reference)
Safety Information
Safety Statements  24/25
HS Code  29339900
Toxicity LDLo orl-rat: 500 mg/kg OYYAA2 56,67,1998

Pitavastatin calcium Usage And Synthesis
Statin lipid-lowering drugs Pitavastatin calcium is jointly developed by two companies Nissan Chemical and Kowa Co.it is the first total synthesis HMG-CoA reductase inhibitor, it belongs to statin drugs ,it reduces the ability of the liver to manufacture cholesterol mainly through inhibition of some liver enzymes called HMGCo-A reductase , thus it improves the elevated blood cholesterol levels, it is primarily used for the treatment of hypercholesterolemia and familial hypercholesterolemia patients,its lipid-lowering effect is very good, it is the most potent lipid-lowering drug so far.
Pharmacological effects Inhibition of HMG-CoA reductase: pitavastatin calcium has a strongly antagonistic inhibition effect on HMG-CoA enzyme , IC50 value is 6.8 nmol/L, and its intensity is 24 times of simvastatin, while it is 68 times of fluvastatin.
It Hinders the synthesis of cholesterol: the ability to effectively inhibit the process of generating cholesterol in human hepatocytes HepG2 , IC50 value is 5.8nmol/L, and its intensity is 29 times of simvastatin, it is 57 times that of atorvastatin. But pitavastatin calcium inhibition effect on each enzyme in cholesterol generation after generation of mevalonate is very weak.
It Increases LDL receptor density: pitavastatin induces the synthesis of LDS receptor mRNA in the ultra-low concentration of 1μmol/L, it can increase the number of LDS receptor mRNA , it results in the increasing of LDL receptor density , thereby it promotes clearance of LDL , so that plasma LDL-plasma total cholesterol concentration and triglyceride concentration decrease.

Product Name: Pitavastatin calcium
Synonyms: 147526-32-7 Pitavastatin Calcium;Pitavastatin Calcuim;Pitavastatin calcium, >=98.5%;Pitavastatin (calcium salt);monocalciumbis[(3R,5S,6E)-7-(2-Cyclopropyl-4-(4-Fluorophenyl)-3-Quinolyl)-3,5-Dihydroxy-6-heptenoate](+)a- Phenethylamine Sal;Pitavastatin Calciu;Calcium (3R,5S,E)-7-(2-cyclopropyl-4-(4-fluorophenyl)-quinolin-3-yl)-3,5-dihydroxyhept-6-enoat;PITAVASTATIN CALCIUM 3S-5R ISOMER IMP
CAS: 147526-32-7
MF: C50H46CaF2N2O8
MW: 880.98
EINECS: 807-641-2
Product Categories: Cardiovascular Series;Active Pharmaceutical Ingredients;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;chemical;API;Livalo
Mol File: 147526-32-7.mol

Pitavastatin calcium Chemical Properties
alpha  D20 +23.1° (c = 1.00 in acetonitrile/water)
CAS DataBase Reference 147526-32-7(CAS DataBase Reference)
Safety Information
Safety Statements  24/25
HS Code  29339900
Toxicity LDLo orl-rat: 500 mg/kg OYYAA2 56,67,1998

Pitavastatin calcium Usage And Synthesis
Statin lipid-lowering drugs Pitavastatin calcium is jointly developed by two companies Nissan Chemical and Kowa Co.it is the first total synthesis HMG-CoA reductase inhibitor, it belongs to statin drugs ,it reduces the ability of the liver to manufacture cholesterol mainly through inhibition of some liver enzymes called HMGCo-A reductase , thus it improves the elevated blood cholesterol levels, it is primarily used for the treatment of hypercholesterolemia and familial hypercholesterolemia patients,its lipid-lowering effect is very good, it is the most potent lipid-lowering drug so far.
Pharmacological effects Inhibition of HMG-CoA reductase: pitavastatin calcium has a strongly antagonistic inhibition effect on HMG-CoA enzyme , IC50 value is 6.8 nmol/L, and its intensity is 24 times of simvastatin, while it is 68 times of fluvastatin.
It Hinders the synthesis of cholesterol: the ability to effectively inhibit the process of generating cholesterol in human hepatocytes HepG2 , IC50 value is 5.8nmol/L, and its intensity is 29 times of simvastatin, it is 57 times that of atorvastatin. But pitavastatin calcium inhibition effect on each enzyme in cholesterol generation after generation of mevalonate is very weak.
It Increases LDL receptor density: pitavastatin induces the synthesis of LDS receptor mRNA in the ultra-low concentration of 1μmol/L, it can increase the number of LDS receptor mRNA , it results in the increasing of LDL receptor density , thereby it promotes clearance of LDL , so that plasma LDL-plasma total cholesterol concentration and triglyceride concentration decrease.